Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.

GSK today announced that it has filed a new drug submission for bepirovirsen for regulatory review in Canada. Bepirovirsen is ...

Policy that recommends offering hep B vaccine at birth only to babies perceived to be at risk will lead to increased numbers ...

Amid policy shifts and a rise in misinformation fueling vaccine hesitancy, fewer infants in the U.S. are receiving the ...

About 90% of infants infected at birth go on to develop chronic infection ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has ...

Hepatitis affects 287 million globally, often undetected until severe liver damage, says the WHO. Early testing, awareness, ...

The revised guidelines also will lead to more than $20 million in extra health care costs, the research shows.

Nearly 287 million people worldwide live with hepatitis B or C, yet most remain undiagnosed until severe liver damage occurs.

Researchers found that the decision to delay the once-universal hepatitis B shot for babies will likely cause a surge in ...

Some 254 million people live with a chronic hepatitis B (HBV) infection that is often asymptomatic for decades, only to ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an ...